Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

There is debate surrounding which treatment is superior in overall survival (OS) rates in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC); first-line tyrosine kinase inhibitor (TKI) followed by second-line platinum-based doublet chemotherapy (PCT), or...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Lifen, Wang, Jin, Long, Guoxian, Jiang, Yueqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338926/
https://www.ncbi.nlm.nih.gov/pubmed/28280362
http://dx.doi.org/10.2147/OTT.S128187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338926/
https://www.ncbi.nlm.nih.gov/pubmed/28280362
http://dx.doi.org/10.2147/OTT.S128187

Ejemplares similares